Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.
Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.
SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.
Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.
A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.
"And the winner is- 'compliant concept' - Michael Sauter and his team receive the CTI Medtech Award 2010" was the announcement heard in the Casino in Bern on August 31st. The Medtech Event organized by the CTI, the Swiss Innovation Promotion Agency, is the meeting place for all the main players in the medical technology branch in the country.
Cumberland Pharmaceuticals Inc. today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, which was published in the August edition of the peer-reviewed journal Pain Medicine, concludes that IV ibuprofen significantly decreased pain and morphine use when compared with placebo.
The Detroit Medical Center (DMC) achieved significant improvements in patient safety and quality of care, while also saving more than $5 million in costs last year, thanks to efficiencies created by its system-wide Electronic Medical Record (EMR). This system manages nearly all of the DMC's patient health information via new computer-based technology.
Stryker Corporation announced today a definitive agreement to acquire privately held Gaymar Industries. Under the terms of the agreement, Stryker will acquire Gaymar Industries for approximately $150 million in an all-cash transaction.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Wound Management Technologies, Inc. announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists.
To meet the escalating patient care, research and healthcare education needs for a rapidly aging population, a university-wide Consortium on Aging has been established at The University of Texas Health Science Center at Houston (UTHealth).
The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).
Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.
Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, reported today its financial results for the quarter and six months ended June 30, 2010.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2010.
CareView Communications, Inc. ("CareView" or the "Company"), an information technology provider to the healthcare industry, announced that it has filed a new patent with the United States Patent and Trademark Office to cover an innovative technology that will assist hospitals and other medical facilities in their efforts to prevent decubitus ulcers or "bed sores" experienced by patients. CareView's new product covered by the pending patent uses the CareView System monitoring system to ensure timely patient movement which assists caregivers in the prevention and treatment of bed sores.
Amputation, one of the most devastating and costly consequences of diabetes, can be prevented when patients are treated by podiatric physicians. That's the finding of a national, large-scale study co-authored by Dr. James Wrobel, DPM, MS, Associate Professor of Medicine at Rosalind Franklin University of Medicine and Science.
Hospital-acquired infections are the leading cause of potentially preventable mortality among pediatric patients, according to a study of pediatric patient-safety incidents issued today by HealthGrades, the leading independent health care ratings organization.
A VOA News editorial by the U.S. government reflects on last month's International AIDS Conference-AIDS 2010, including key advancements such as the vaginal microbicide gel found to offer women some protection against HIV infection as well discussions about funding for the fight against HIV/AIDS and how the "criminalization of drug abuse and persecution of homosexuals" in the world is compromising efforts to prevent the spread of the disease.
Telormedix, a clinical stage biopharmaceutical company using targeted immunity to treat cancer and other diseases, today announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix's adjuvant, TMX-201, in connection with immunization for Malaria and Buruli Ulcer.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.